# Intrathecal Pemetrexed for Leptomeningeal Metastasis

> **NCT05289908** · PHASE1,PHASE2 · COMPLETED · sponsor: **The First Hospital of Jilin University** · enrollment: 34 (actual)

## Conditions studied

- Leptomeningeal Metastases

## Interventions

- **DRUG:** Pemetrexed (1)
- **DRUG:** Pemetrexed (2)
- **DRUG:** Folic Acid
- **DRUG:** Vitamin B12
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT05289908
- **Lead sponsor:** The First Hospital of Jilin University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-21
- **Primary completion:** 2023-03-20
- **Final completion:** 2024-03-31
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2025-05-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05289908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05289908, "Intrathecal Pemetrexed for Leptomeningeal Metastasis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05289908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*